Cite
HARVARD Citation
Vergnenegre, A. et al. (2020). Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04). Cancer medicine. pp. 432-439. [Online].